OPKO Health (NASDAQ:OPK) Upgraded at StockNews.com

OPKO Health (NASDAQ:OPK - Get Free Report) was upgraded by research analysts at StockNews.com from a "sell" rating to a "hold" rating in a note issued to investors on Monday.

Several other equities research analysts have also commented on OPK. Barrington Research restated an "outperform" rating and set a $2.25 target price on shares of OPKO Health in a research report on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $3.00 price target on shares of OPKO Health in a report on Monday.

OPKO Health Trading Up 0.5 %

NASDAQ:OPK traded up $0.01 on Monday, reaching $1.90. 5,853,623 shares of the stock traded hands, compared to its average volume of 4,711,981. The firm has a market capitalization of $1.30 billion, a price-to-earnings ratio of -10.00 and a beta of 1.63. OPKO Health has a 1-year low of $0.86 and a 1-year high of $2.04. The company has a current ratio of 2.97, a quick ratio of 2.69 and a debt-to-equity ratio of 0.30. The company's 50 day moving average is $1.58 and its 200-day moving average is $1.56.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.09. The business had revenue of $183.60 million during the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. Equities research analysts anticipate that OPKO Health will post -0.25 EPS for the current fiscal year.

Remove Ads

Insider Activity

In other OPKO Health news, CEO Phillip Md Et Al Frost purchased 500,000 shares of OPKO Health stock in a transaction that occurred on Wednesday, December 11th. The stock was acquired at an average price of $1.56 per share, with a total value of $780,000.00. Following the transaction, the chief executive officer now owns 212,411,477 shares in the company, valued at $331,361,904.12. This trade represents a 0.24 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders bought a total of 1,389,971 shares of company stock worth $2,124,442 in the last three months. Company insiders own 47.26% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in OPK. FMR LLC raised its holdings in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 11,089 shares during the last quarter. Orion Portfolio Solutions LLC purchased a new stake in shares of OPKO Health in the third quarter worth approximately $45,000. Cibc World Markets Corp bought a new position in shares of OPKO Health in the fourth quarter valued at approximately $45,000. Zacks Investment Management purchased a new position in shares of OPKO Health during the fourth quarter valued at approximately $49,000. Finally, Ieq Capital LLC bought a new stake in OPKO Health during the fourth quarter worth $52,000. 64.63% of the stock is owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.